Effect of adenosine A2A receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum

Neurotoxicity Research

Volumn 15, Issue 2, 2009, Pages 155-166

  Gołembiowska, Krystyna ^a   Dziubina, Anna ^a   Kowalska, Magdalena ^a   Kamińska, Katarzyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine A2A receptor antagonists; Oxidative stress; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 (2 [7 AMINO 2 (2 FURYL)[1,2,4]TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL)PHENOL; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 HYDROXYBENZOIC ACID; 8 (3 CHLOROSTYRYL)CAFFEINE; ADENOSINE A2A RECEPTOR ANTAGONIST; BENSERAZIDE; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; HYDROXYL RADICAL; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ELECTROCHEMICAL DETECTION; EXTRACELLULAR SPACE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LONG TERM EXPOSURE; LOW DRUG DOSE; MALE; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; AREA UNDER CURVE; BENSERAZIDE; CATALEPSY; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALOPERIDOL; HOMOVANILLIC ACID; HYDROXYL RADICAL; LEVODOPA; MALE; MICRODIALYSIS; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; TIME FACTORS; TRIAZINES; TRIAZOLES; XANTHINES;

RATTUS;

EID: 70349728584     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9016-2     Document Type: Article

References (54)

1. 2A receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. Brain Res 1191:192-199
2. Ascherio A, Zhang SH, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
3. 2A receptor antagonists. Br J Pharmacol 135:1435-1442
4. Bishnoi M, Chopra K, Kulkarni SK (2007) Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep 59:181-191
5. Block ML, Zecca L, Hong J-S (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69
6. 2A antagonist CSC in the 6-OHDA rat model of parkinsonism: Effect on the activity of striatal output pathways. Exp Brain Res 165:362-374
7. Buu NT, Angers M (1987) Effects of different monoamine oxidase inhibitors on the metabolism of L-DOPA in the rat brain. Biochem Pharmacol 36:1731-1735
8. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243
9. Chen J-F, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200
10. Chen J-F, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143
11. 2A receptor antagonism. J Biol Chem 277:36040-36044
12. 2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 83:310-331
13. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28:425-433
14. Cleren C, Vilpoux C, Dourmap N, Bonnet J-J, Costentin J (1999) Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice. Brain Res 830:314-319
15. Daré E, Schulte G, Karovic O, Hammarberg C, Fredholm BB (2007) Modulation of glial cell functions by adenosine receptors. Physiol Behav 92:15-20
16. Fahn S, Sulzer D (2004) Neurodegeneration and Neuroprotection in Parkinson's Disease. NeuroRx 1:139-154
17. Gluck MR, Zeevalk GD (2004) Inhibition of brain mitochondrial respiration by dopamine and its metabolites: Implications for Parkinson's disease and catecholamine-associated diseases. J Neurochem 91:788-795
18. 2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum. Brain Res 998:208-217
19. 2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 47:414-426
20. Halliwell B (2006) Oxidative stress and neurodegeneration: Where we now? J Neurochem 97:1634-1658
21. Heikkila RE, Cohen G (1971) Inhibition of biogenis amine uptake by hydrogen peroxide: A mechanism for the toxic effects of 6-OHDA. Science 172:1257-1258
22. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80:262-270
23. Jana S, Maiti AK, Bagh MB, Banerjee K, Das A, Roy A, Chakrabarti S (2007) Dopamine but not 3,4-dihydroxyphenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinine products: Implications in Parkinson's disease. Brain Res 1139:195-200
24. 2A receptor agonists and antagonists. Neuroscience 85:229-237
25. 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513
26. Levitt P, Pintar JE, Breakfield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79:6385-6389
27. 2A receptor antagonist istradefylline (KW-6002) reduces "Off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63:295-302
28. 2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 959:243-250
29. Migheli R, Godani C, Sciola L, Delogu MR, Serra PA, Zangani D, De Natale G, Miele E, Desole MS (1999) Enhancing effect of manganese on L-DOPA-induced apoptosis in PC12 cells: Role of oxidative stress. J Neurochem 73:1155-1163
30. 2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. Prog Neurobiol 83:293-309
31. Nakao N, Nakai K, Itakura T (1997) Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro. Brain Res 777:202-209
32. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y (2000) Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: A microdialysis study. Neuroscience 100:53-62
33. Oreland L (1991) Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand 84(Suppl 136):60-65
34. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, San Diego
35. Phillis JW (1995) The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705:79-84
36. Pierri M, Vaudano E, Sager T, Englund U (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517-524
37. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89:152-156
38. Pocock JM, Kettenmann H (2007) Neurotransmitter receptors on microglia. Trends Neurosci 30:527-535
39. Pollack AE, Fink JS (1995) Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68:721-728
40. 2A receptor reduces, through a presynaptic mechanism, quinolic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22:1967-1975
41. Popoli P, Blum D, Pintor A, Tebano MT, Frank C, Gianfriddo M, Domenici MR, Schiffmann SN, Pedata F (2004) The controversial role of adenosine receptor antagonists as neuroprotective agents. Curr Med Chem - CNS Agents 4:35-45
42. Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini A-B, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34:715-723
43. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung K-H, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679
44. Rowe DB, Le W, Smith RG, Appel SH (1998) Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 53:551-558
45. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Bchman VL (2003) Induction of neuronal death by alpha-synuclein. Eur J Neurosci 12:3073-3077
46. 2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95:919-929
47. 2A receptors in Parkinson's disease. Trends Neurosci 29:647-654
48. Serra PA, Esposito G, Enrico P, Mura MA, Migheli R, Delogu MR, Miele M, Desole MS, Grella G, Miele E (2000) Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: Potential implications to L-DOPA long-term therapy of Parkinson's disease. Br J Pharmacol 130:937-945
49. Simon P, Langwiński R, Boissier JR (1969) Comparaison de diffěrents tests d'ěvaluation de la catalepsie chez le rat. Thěrapie 24:985-995
50. 2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 53:783-789
51. 2A receptor agonist and antagonist. Eur J Pharmacol 287:295-302
52. 2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41:160-171
53. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100:6145-6150
54. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310